BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%HomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 14 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%Zacks Equity ResearchZacksJanuary 10, 2020ReblogShareTweetShareBioMarin Pharmaceutical Inc. BMRN was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $78.77 to $86.37 in the past one-month time frame.The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for BioMarin. So, make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.BioMarin currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.BioMarin Pharmaceutical Inc. PriceBioMarin Pharmaceutical Inc. PriceMoreBioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. QuoteInvestors interested in the Medical - Biomedical and Genetics industry may consider Amarin Corporation PLC AMRN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is BMRN going up? Or down? Predict to see what others think:Up or Down5 Stocks Set to DoubleEach was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in FocusZacksStock Market News for Feb 27, 2020ZacksBioMarin Pharmaceutical (BMRN) Q4 Earnings Top EstimatesZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMincor Resources (ASX:MCR) Is In A Strong Position To Grow Its BusinessSimply Wall St.What the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoEiffage SA Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next YearSimply Wall St.Loan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance Video